It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Sygnature Discovery accelerates ion channel drug discovery by combining bespoke cell models with robust electrophysiology and validated high throughput screening, so you can progress TMEM175 programs with confidence.
Advance your TMEM175 drug discovery programs with our validated assay platform. We provide wild type and disease relevant variant TMEM175 models that support high throughput screening, detailed electrophysiology, and pharmacological profiling to speed therapeutic innovation.
TMEM175 is a constitutively active lysosomal potassium channel that contributes to lysosomal pH regulation, membrane potential, and autophagy. Impaired TMEM175 function has been linked to alpha synuclein aggregation and reduced protein clearance, both of which are important in Parkinson’s disease. Loss of function and gain of function coding variants are associated with disease risk, making TMEM175 a promising yet underexplored target in ion channel drug discovery. Our TMEM175 platform is designed to enable strategies that restore lysosomal homeostasis and address neurodegenerative disease biology.
Access the Assays You Need
Sygnature Discovery offers proprietary cell lines expressing TMEM175, including wild type and variant forms as well as key species orthologs. Our validated cell models and electrophysiology platforms help you:
Accelerate hit identification and lead optimization
Explore functional effects of disease-relevant TMEM175 variants
Confidently advance TMEM175-targeting drug discovery programs
Need something specific? Our experienced cell line generation team can develop and validate additional TMEM175 variants to support your research.
Off-the-Shelf TMEM175 Assays
TMEM175 (human)
TMEM175 (LoF)
TMEM175 (GoF)
TMEM175 (mouse)
TMEM175 (rat)
TMEM175 (dog)
TMEM175 (monkey)
Investigate TMEM175 Biology in Depth
Our TMEM175 platform gives you the tools to interrogate biology and accelerate discovery in one integrated workflow. You can:
Assess activation under extracellular acidification
Measure compound efficacy across disease-relevant genetic backgrounds
Access species orthologs and disease-relevant cell lines
Run robust electrophysiology and validated high-throughput screening assays
With side-by-side comparisons of wild type, loss-of-function, and gain-of-function variants, you can uncover how genetic diversity shapes TMEM175 activity and identify new ways to modulate the channel.
Our validated platform detects subtle functional changes across TMEM175 variants and quantifies modulator activity, enabling discovery of tools to restore lysosomal balance and advance neurodegenerative research.
SSM Electrophysiology for Lysosomal Ion Channels
Complementing our automated patch clamp capabilities, we also offer solid supported membrane-based electrophysiology, an efficient approach for intracellular lysosomal channels such as TMEM175. This enables reconstituted lysosomal membranes containing TMEM175, evaluation of both activators and inhibitors in a 96-well format, and orthogonal validation to support screening findings and confirm organellar ion channel modulation.
Representative TMEM175 current traces before (grey line) and during the presence of increasing concentrations of the agonist DCPIB (blue lines). Currents are evoked by a 500 ms ramp from -80 mV to +80mV, followed by a 500 ms step from -80 mV to +80 mV before returning to the holding potential of 0mV.
Representative TMEM175 current traces measured in the presence of increasing concentrations of the agonist DCPIB (0.3-30 µM) using solid-supported membrane (SSM) electrophysiology platform.
TMEM175 screening using a multi-platform approach – including electrophysiology and fluorescence-based assays – enables comprehensive…
Case Studies
Related Capabilities
We bring together a dynamic blend of new talent and experiences pharmaceutical industry experts from around the world, delivering excellence across each stage of discovery.
Comprehensive ion channel assays and bespoke cell lines deliver high-fidelity screening and safety insights, accelerating hit-to-lead and optimization.
Precise ion channel and transporter insights through tailored electrophysiology studies supporting target validation, hit identification, and lead optimization decisions.
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.
